Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of ...

Actuate Therapeutics reports elraglusib shows anti-tumor activity with 2 durable complete responses and ~62% disease control rate in 8 relapsed/refractory Ewing and Ewing-related sarcoma patients. Enrollment continues with topline data expected in 1H 2025.